The Pattern, Management, and Outcomes of Recurrence Following Cytoreductive Surgery for Pseudomyxoma Peritonei
ANZ Journal of Surgery · 2025
DOI: 10.1111/ans.70179 ↗At a glance
Journal article in ANZ Journal of Surgery, 2025. Written by Rennie Xinrui Qin and 6 co-authors. Institution: Department of General Surgery, Te Whatu Ora Waikato, Hamilton, New Zealand. Major MEDLINE topics: Pseudomyxoma Peritonei, Cytoreduction Surgical Procedures, Neoplasm Recurrence, Local, Peritoneal Neoplasms. 18 references. Funded by: Waikato Medical Research Foundation.
Abstract (original language)
Backgrounds We aimed to assess the pattern, management, and outcomes of recurrent pseudomyxoma peritonei (PMP) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) and compare repeat and index CRS/HIPEC.
Methods
A retrospective review was performed of patients undergoing CRS/HIPEC for PMP between 01/01/2008 and 30/06/2022 at a tertiary referral center in New Zealand. Multivariate logistic regression was used to identify independent predictors of repeat CRS/HIPEC. Overall survival (OS) of PMP recurrence was stratified according to management strategy.
Results
Among 183 primary CRS/HIPEC for appendiceal PMP, 154 (84.2%) achieved complete cytoreduction. Median follow‐up duration was 72.1 months. Forty‐nine recurred (31.8%). 40 (81.6%) cases of recurrence were isolated to the peritoneal cavity, and 47 (95.9%) occurred within 5 years. 27 (55.1%) underwent repeat curative‐intent surgery. 22 (44.9%) were managed with palliative intent. Age > 65 and high‐grade carcinoma peritonei (HG) were independent negative predictors of repeat curative‐intent surgery. Five‐year overall survival was significantly higher in patients undergoing repeat curative‐intent surgery (80.3%) compared to those managed with palliative intent (44.8%) (HR = 0.23, p < 0.001). Curative‐intent repeat surgery was an independent predictor of overall survival in PMP recurrences. Compared to primary CRS/HIPEC, repeat CRS/HIPEC were less extensive procedures conducted in cases with a lower peritoneal cancer index. Repeat CRS/HIPEC had similar peri‐operative morbidity and long‐term survival to primary procedures.
Conclusions
Repeat CRS/HIPEC for recurrent PMP is feasible and has similar safety and efficacy to index operations. Favorable long‐term outcomes are achievable in well‐selected patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of General Surgery, Te Whatu Ora Waikato, Hamilton, New Zealand.
- School of Population Health, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
- Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
ORCID profiles: Rennie Xinrui Qin, Jesse Fischer
Funding
- Waikato Medical Research Foundation
Cite
APA
Qin, R. X., Puloka, T., Lim, J. H., Staheli, C., Lolohea, S., Ly, J., & Fischer, J. (2025). The Pattern, Management, and Outcomes of Recurrence Following Cytoreductive Surgery for Pseudomyxoma Peritonei. ANZ Journal of Surgery. https://doi.org/10.1111/ans.70179
Vancouver
Qin RX, Puloka T, Lim JH, Staheli C, Lolohea S, Ly J, et al. The Pattern, Management, and Outcomes of Recurrence Following Cytoreductive Surgery for Pseudomyxoma Peritonei. ANZ Journal of Surgery. 2025. doi:10.1111/ans.70179
BibTeX
@article{Qin2025,
author = {Qin, Rennie Xinrui and Puloka, Tilisi and Lim, Jia Hui and Staheli, Caro and Lolohea, Simione and Ly, Jasen and Fischer, Jesse},
title = {The Pattern, Management, and Outcomes of Recurrence Following Cytoreductive Surgery for Pseudomyxoma Peritonei},
journal = {ANZ Journal of Surgery},
year = {2025},
doi = {10.1111/ans.70179}
}
EUVIMED